March 2013
Pharmaceutical Executive
Authored by Mary R. Henninger, Ph.D. and Mark J. Feldstein, Ph.D.
Corporate IP is a business tool. It is not an end in itself, to be framed and displayed on the office wall or the company website. Much like an investment portfolio, an IP portfolio must be designed to meet specific objectives—financing, market entry, acquisition, etc.—and be regularly revised as conditions change. Early planning and continued diligence by executives and their IP counsel are required to ensure that patent strategies are aligned with and advance core business objectives. Ultimately, this maximizes IP and corporate value. Creating a patent strategy is particularly critical to emerging and mid-sized biotechnology companies, as patents are a primary consideration for Big Pharma as it looks to find new sources of innovation and fill the new product pipeline.
Originally published by Pharmaceutical Executive(www.pharmexec.com). This article is for informational purposes, is not intended to constitute legal advice, and may be considered advertising under applicable state laws. This article is only the opinion of the authors and is not attributable to Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, or the firm's clients.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Conference
Boston Intellectual Property Law Association 4th Annual Symposium
April 10-11, 2024
Boston
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.